Adjuvant Chemotherapy for Stage II Colon Cancer: Practice Patterns and Effectiveness in the General Population

Clinical Oncology

Volumn 29, Issue 1, 2017, Pages e29-e38

  Booth, C M ^a,b   Nanji, S ^b   Wei, X ^a   Peng, Y ^a,b   Biagi, J J ^b   Hanna, T P ^a,b   Krzyzanowska, M K ^c   Mackillop, W J ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chemotherapy; colon cancer; effectiveness; quality of care; surgery

Indexed keywords

CAPECITABINE; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COHORT ANALYSIS; COLON CANCER; DISEASE SEVERITY; FEMALE; GROUPS BY AGE; HIGH RISK PATIENT; HISTOLOGY; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL ANALYSIS; SURVIVAL RATE; CANCER STAGING; COLONIC NEOPLASMS; EPIDEMIOLOGY; MIDDLE AGED; ONTARIO; PROCEDURES; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ONTARIO; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84994735210     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2016.09.001     Document Type: Article

References (29)

1. [1] Benson, A.B. III, Schrag, D., Somerfield, M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 (2004), 3408–3419.
2. [2] Labianca, R., Nordlinger, B., Beretta, G.D., et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:Suppl. 6 (2013), vi64–vi72.
3. [3] National Comprehensive Cancer Network, NCCN Guidelines Colon Cancer. 2015.
4. [4] International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators, Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345 (1995), 939–944.
5. [5] International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators, Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17 (1999), 1356–1363.
6. [6] Gill, S., Loprinzi, C.L., Sargent, D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 22 (2004), 1797–1806.
7. [7] Figueredo, A., Charette, M.L., Maroun, J., et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22 (2004), 3395–3407.
8. [8] Booth, C.M., Mackillop, W.J., Translating new medical therapies into societal benefit: the role of population-based outcome studies. JAMA 300 (2008), 2177–2179.
9. [9] Booth, C.M., Tannock, I.F., Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 110 (2014), 551–555.
10. [10] Kumar, A., Kennecke, H.F., Renouf, D.J., et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer 121 (2015), 527–534.
11. [11] Weiss, J.M., Schumacher, J., Allen, G.O., et al. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data. Ann Surg Oncol 21 (2014), 1781–1791.
12. [12] Boland, G.M., Chang, G.J., Haynes, A.B., et al. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer 119 (2013), 1593–1601.
13. [13] Chagpar, R., Xing, Y., Chiang, Y.J., et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol 30 (2012), 972–979.
14. [14] O'Connor, E.S., Greenblatt, D.Y., Loconte, N.K., et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29 (2011), 3381–3388.
15. [15] Schrag, D., Rifas-Shiman, S., Saltz, L., et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20 (2002), 3999–4005.
16. [16] McKenzie, S., Nelson, R., Mailey, B., et al. Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. Cancer 117 (2011), 5493–5499.
17. [17] Murphy, C.C., Harlan, L.C., Lund, J.L., et al. Patterns of colorectal cancer care in the United States: 1990–2010. J Natl Cancer Inst 107 (2015), 1–11.
18. [18] Clarke, E.A., Marrett, L.D., Krieger, N., Cancer registration in Ontario: a computer approach. Jenson, O.M., Parkin, D.M., MacLennan, R., (eds.) Cancer registration principles and methods, 1991, IARC, Lyon, 246–257.
19. [19] Li, X., King, C., deGara, C., et al. Validation of colorectal cancer surgery data from administrative data sources. BMC Med Res Methodol, 12, 2012, 97.
20. [20] Mackillop, W.J., Zhang-Salomons, J., Groome, P.A., et al. Socioeconomic status and cancer survival in Ontario. J Clin Oncol 15 (1997), 1680–1689.
21. [21] Deyo, R.A., Cherkin, D.C., Ciol, M.A., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992), 613–619.
22. [22] Sanoff, H.K., Carpenter, W.R., Sturmer, T., et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 30 (2012), 2624–2634.
23. [23] Rubin, D.B., Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 (1997), 757–763.
24. [24] Sundararajan, V., Mitra, N., Jacobson, J.S., et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 136 (2002), 349–357.
25. [25] Sanoff, H.K., Carpenter, W.R., Martin, C.F., et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 104 (2012), 211–227.
26. [26] Zuckerman, I.H., Rapp, T., Onukwugha, E., et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc 57 (2009), 1403–1410.
27. [27] Schrag, D., Cramer, L.D., Bach, P.B., et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 93 (2001), 850–857.
28. [28] Williams, J., Young, W., A summary of studies on the quality of health care administrative databases in Canada. Goel, V., Williams, J.I., Anderson, G.M., et al. (eds.) Patterns of health care in Ontario: the ICES practice atlas, 2nd edn., 1996, Canadian Medical Association, Ottawa, 339–345.
29. [29] Booth, C.M., Nanji, S., Wei, X., et al. Use and effectiveness of adjuvant chemotherapy for stage III colon cancer: a population-based study. J Natl Compr Canc Netw 14 (2016), 47–56.